<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied the efficacy of high doses (100,000 IU intravenously (IV)/twice a week) of human recombinant erythropoietin (rHuEpo) in patients with transfusion dependent <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Rationale for such dose of IV Epo was the poor in vitro response of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> erythroid progenitors (CFU-E) to physiological concentrations of Epo, and the usual high endogenous serum Epo levels of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="2" pm="."><plain>Seventeen patients (nine males, eight females) were included, five refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> (RA), six RA with blasts excess (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), five RA with ringed sideroblasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Tolerance was good, except in three patients who experienced severe <z:e sem="disease" ids="C1558931" disease_type="Disease or Syndrome" abbrv="">flu-like syndrome</z:e> after Epo injection </plain></SENT>
<SENT sid="4" pm="."><plain>None of the patients showed <z:hpo ids='HP_0000822'>hypertension</z:hpo> or developed anti rHuEpo antibodies </plain></SENT>
<SENT sid="5" pm="."><plain>Three patients (17.6%) with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> had 35-60% reduction of transfusion requirements </plain></SENT>
<SENT sid="6" pm="."><plain>No progression of disease occurred </plain></SENT>
<SENT sid="7" pm="."><plain>Percentage of erythroblasts, endogenous baseline Epo level and in vitro cultures of erythroid progenitors did not correlate with response to Epo treatment </plain></SENT>
<SENT sid="8" pm="."><plain>This study shows that very high IV doses induce only seldom and partial improvement in the status of transfusion dependent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>This rate of response, not higher than described with lower dosage, probably represents the maximum expectable response to rHuEpo in this category of patients </plain></SENT>
</text></document>